RU2636456C2 - Гликозилированный полипептид и содержащая его фармацевтическая композиция - Google Patents

Гликозилированный полипептид и содержащая его фармацевтическая композиция Download PDF

Info

Publication number
RU2636456C2
RU2636456C2 RU2014116550A RU2014116550A RU2636456C2 RU 2636456 C2 RU2636456 C2 RU 2636456C2 RU 2014116550 A RU2014116550 A RU 2014116550A RU 2014116550 A RU2014116550 A RU 2014116550A RU 2636456 C2 RU2636456 C2 RU 2636456C2
Authority
RU
Russia
Prior art keywords
fmoc
sugar chain
polypeptide
solution
glycosylated
Prior art date
Application number
RU2014116550A
Other languages
English (en)
Russian (ru)
Other versions
RU2014116550A (ru
Inventor
Идзуми САКАМОТО
Кадзухиро ФУКАЭ
Кацунари ТЭДЗУКА
Кэйсукэ ТАДЗУРУ
Масатоси МАЭДА
Ясухиро КАДЗИХАРА
Такаси ЦУДЗИ
Original Assignee
Глитек, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глитек, Инк. filed Critical Глитек, Инк.
Publication of RU2014116550A publication Critical patent/RU2014116550A/ru
Application granted granted Critical
Publication of RU2636456C2 publication Critical patent/RU2636456C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C07K1/026—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution by fragment condensation in solution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2014116550A 2011-10-01 2012-09-28 Гликозилированный полипептид и содержащая его фармацевтическая композиция RU2636456C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011218793 2011-10-01
JP2011-218793 2011-10-01
PCT/JP2012/075262 WO2013047846A1 (ja) 2011-10-01 2012-09-28 糖鎖付加ポリペプチドおよび当該ポリペプチドを含む医薬組成物

Publications (2)

Publication Number Publication Date
RU2014116550A RU2014116550A (ru) 2015-10-27
RU2636456C2 true RU2636456C2 (ru) 2017-11-23

Family

ID=47995870

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014116550A RU2636456C2 (ru) 2011-10-01 2012-09-28 Гликозилированный полипептид и содержащая его фармацевтическая композиция

Country Status (16)

Country Link
US (1) US10358470B2 (enExample)
EP (1) EP2762489B1 (enExample)
JP (1) JP6153470B2 (enExample)
KR (1) KR101979045B1 (enExample)
CN (2) CN104080803B (enExample)
AU (1) AU2012317325B2 (enExample)
BR (1) BR112014007766B1 (enExample)
CA (1) CA2850469C (enExample)
DK (1) DK2762489T3 (enExample)
IN (1) IN2014CN02982A (enExample)
MY (1) MY168902A (enExample)
PH (1) PH12014500694B1 (enExample)
RU (1) RU2636456C2 (enExample)
SG (2) SG11201401071YA (enExample)
TW (1) TWI633115B (enExample)
WO (1) WO2013047846A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101979045B1 (ko) 2011-10-01 2019-05-15 가부시키가이샤 도우사 고가쿠 겐큐쇼 당쇄 부가 폴리펩티드 및 상기 폴리펩티드를 포함하는 의약 조성물
DK2982686T3 (en) 2013-03-29 2018-10-08 Glytech Inc POLYPEPTIDE WITH SIALYLED SUGAR CHAIN CONNECTED
CN114685645B (zh) * 2020-12-30 2025-03-21 深圳翰宇药业股份有限公司 一种索玛鲁肽的合成方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023472A2 (en) * 1998-10-16 2000-04-27 Biogen, Inc. Interferon-beta fusion proteins and uses
WO2003075944A2 (en) * 2002-03-12 2003-09-18 Maxygen Aps Interferon beta-like molecules for treatment of stroke
EA009289B1 (ru) * 2002-09-27 2007-12-28 Байоджен Айдек Ма Инк. ЛЕЧЕНИЕ ХРОНИЧЕСКОЙ ВОСПАЛИТЕЛЬНОЙ ДЕМИЕЛИНИЗИРУЮЩЕЙ ПОЛИНЕВРОПАТИИ С ИСПОЛЬЗОВАНИЕМ β-ИНТЕРФЕРОНА
US20080003202A1 (en) * 2006-03-28 2008-01-03 Thierry Guyon Modified interferon-beta (IFN-beta) polypeptides
RU2007103479A (ru) * 2004-08-09 2008-09-20 Элиоз Байофарма, Инк. (Сша/Сша) (Us) Синтетические варианты гипергликолизованного протеазо-резистивного полипептида, пероральные композиции и способы применения таких вариантов
WO2010015722A1 (en) * 2008-08-08 2010-02-11 Vib Vzw Cells producing glycoproteins having altered glycosylation patterns and methods and use thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0237019A3 (en) * 1986-03-14 1988-03-09 Toray Industries, Inc. Interferon conjugate and production thereof using recombinant gene
ES2218806T3 (es) 1997-01-16 2004-11-16 Neose Technologies, Inc. Sialilacion practica in vitro de glicoproteinas recombinantes.
DE19717864C2 (de) 1997-04-23 2001-05-17 Fraunhofer Ges Forschung Humanes rekombinantes Interferon-beta, Verfahren zu seiner Herstellung und seine Verwendung
BR9910023A (pt) * 1998-04-28 2000-12-26 Applied Research Systems Conjugados de poliol-ifn-beta
HU229888B1 (en) 1998-10-16 2014-11-28 Biogen Idec Ma Inc Cambridge Polymer conjugates of interferon betha-1a and uses
US6514729B1 (en) 1999-05-12 2003-02-04 Xencor, Inc. Recombinant interferon-beta muteins
DE60037978T2 (de) * 1999-12-08 2008-05-21 Amgen Inc., Thousand Oaks Interferon ähnliche moleküle, und deren verwendungen
US7795002B2 (en) * 2000-06-28 2010-09-14 Glycofi, Inc. Production of galactosylated glycoproteins in lower eukaryotes
AU2001273385B2 (en) 2000-09-08 2005-04-07 Gryphon Therapeutics, Inc. Polymer-modified synthetic proteins
JP2004534523A (ja) 2001-02-27 2004-11-18 マキシゲン・エイピーエス 新規なインターフェロンβ様分子
CA2441095A1 (en) 2001-03-15 2002-09-26 Merck Patent Gesellschaft Mit Beschraenkter Haftung Modified interferon beta with reduced immunogenicity
US7226903B2 (en) * 2001-10-10 2007-06-05 Neose Technologies, Inc. Interferon beta: remodeling and glycoconjugation of interferon beta
EP2305312B1 (en) * 2001-10-10 2015-03-04 ratiopharm GmbH Remodelling and glycoconjugation of follicle-stimulating hormone (FSH)
CA2469487A1 (en) 2001-12-11 2003-07-03 Aventis Pasteur Mutated hiv tat
US7943763B2 (en) 2002-07-05 2011-05-17 Otsuka Chemical Holdings Co., Ltd. Process for preparing glycopeptides having asparagine-linked oligosaccharides, and the glycopeptides
AU2003254641A1 (en) 2002-08-28 2004-03-19 Maxygen Aps Interferon beta-like molecules for treatment of cancer
AU2003277088A1 (en) 2002-10-01 2004-04-23 Xencor, Inc Interferon variants with improved properties
AU2003292792A1 (en) 2002-12-26 2004-07-22 Kajihara, Yasuhiro Sugar-chain asparagine derivatives and processes for the preparation thereof
EP1666496B1 (en) 2003-08-25 2014-03-12 Toray Industries, Inc. Interferon-beta composite
JP2007526317A (ja) 2004-03-01 2007-09-13 エンゾン ファーマスーティカルズ インコーポレイテッド インターフェロン−ベータ・ポリマー結合体
EP1789074A4 (en) 2004-08-09 2009-08-12 Alios Biopharma Inc PROTEASE-RESISTANT HYPERGLYCOSYL SYNTHETIC POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME
KR100781666B1 (ko) 2004-11-02 2007-12-03 신영기 인간 인터페론-베타 변이체
SG155183A1 (en) * 2005-08-26 2009-09-30 Ares Trading Sa Process for the preparation of glycosylated interferon beta
US20080096819A1 (en) 2006-05-02 2008-04-24 Allozyne, Inc. Amino acid substituted molecules
TWI423821B (zh) 2007-06-19 2014-01-21 Glucose-containing glucagon-like peptide-1 peptide
AU2008283317B2 (en) 2007-07-31 2012-08-02 Glytech, Inc. Method for producing peptide
JP2009242372A (ja) 2008-03-11 2009-10-22 Yokohama City Univ 均一な糖鎖構造を有するエリスロポエチン誘導体
JP5604297B2 (ja) 2008-06-17 2014-10-08 株式会社糖鎖工学研究所 糖鎖付加ｇｌｐ−１ペプチド
KR20110067097A (ko) * 2008-08-19 2011-06-21 오츠카 가가쿠 가부시키가이샤 당단백질의 제조방법 및 스크리닝 방법
WO2012051615A1 (en) 2010-10-15 2012-04-19 Transgenrx, Inc. Novel vectors for production of glycosylated interferon
SG193377A1 (en) 2011-03-10 2013-10-30 Glytech Inc Method for producing glycopeptide having sialyl sugar chain, sialyl sugar chain-added amino acid derivative to be used in same, and glycopeptide
ES2774284T3 (es) 2011-06-29 2020-07-20 Kyowa Kirin Co Ltd Método para purificar antitrombina
KR101979045B1 (ko) 2011-10-01 2019-05-15 가부시키가이샤 도우사 고가쿠 겐큐쇼 당쇄 부가 폴리펩티드 및 상기 폴리펩티드를 포함하는 의약 조성물

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023472A2 (en) * 1998-10-16 2000-04-27 Biogen, Inc. Interferon-beta fusion proteins and uses
WO2003075944A2 (en) * 2002-03-12 2003-09-18 Maxygen Aps Interferon beta-like molecules for treatment of stroke
EA009289B1 (ru) * 2002-09-27 2007-12-28 Байоджен Айдек Ма Инк. ЛЕЧЕНИЕ ХРОНИЧЕСКОЙ ВОСПАЛИТЕЛЬНОЙ ДЕМИЕЛИНИЗИРУЮЩЕЙ ПОЛИНЕВРОПАТИИ С ИСПОЛЬЗОВАНИЕМ β-ИНТЕРФЕРОНА
RU2007103479A (ru) * 2004-08-09 2008-09-20 Элиоз Байофарма, Инк. (Сша/Сша) (Us) Синтетические варианты гипергликолизованного протеазо-резистивного полипептида, пероральные композиции и способы применения таких вариантов
US20080003202A1 (en) * 2006-03-28 2008-01-03 Thierry Guyon Modified interferon-beta (IFN-beta) polypeptides
WO2010015722A1 (en) * 2008-08-08 2010-02-11 Vib Vzw Cells producing glycoproteins having altered glycosylation patterns and methods and use thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GREENE T.W. et al. Protective groups in organic synthesis, 2-е издание, John Wiley & Sons, Inc, Canada, 1991, p.473. *
GREENE T.W. et al. Protective groups in organic synthesis, 2-е издание, John Wiley & Sons, Inc, Canada, 1991, p.473. RUNKEL L. et al. Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-β (IFN-β), Pharmaceutical research, 1998, v.15, n. 4, p. 641-646. *
KARPUSAS M. et al. The crystal structure of human interferon beta at 2.2-A resolution, Proc. Natl. Acad. Sci. U.S.A., 1997, v. 94, n. 22, p. 11813-11818. *
RUNKEL L. et al. Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-β (IFN-β), Pharmaceutical research, 1998, v.15, n. 4, p. 641-646. *

Also Published As

Publication number Publication date
EP2762489A9 (en) 2015-02-11
SG10201602076QA (en) 2016-04-28
CA2850469C (en) 2020-07-07
CN104080803A (zh) 2014-10-01
US10358470B2 (en) 2019-07-23
RU2014116550A (ru) 2015-10-27
KR101979045B1 (ko) 2019-05-15
MY168902A (en) 2018-12-04
BR112014007766A2 (pt) 2017-04-04
DK2762489T3 (en) 2018-07-02
CN104080803B (zh) 2020-08-04
JP6153470B2 (ja) 2017-06-28
CN109134642A (zh) 2019-01-04
AU2012317325B2 (en) 2016-10-06
EP2762489B1 (en) 2018-03-28
EP2762489A1 (en) 2014-08-06
US20140369964A1 (en) 2014-12-18
EP2762489A4 (en) 2015-05-06
IN2014CN02982A (enExample) 2015-07-03
SG11201401071YA (en) 2014-08-28
CA2850469A1 (en) 2013-04-04
TW201321404A (zh) 2013-06-01
KR20140095051A (ko) 2014-07-31
PH12014500694B1 (en) 2020-01-31
BR112014007766B1 (pt) 2022-05-10
WO2013047846A1 (ja) 2013-04-04
TWI633115B (zh) 2018-08-21
JPWO2013047846A1 (ja) 2015-03-30
PH12014500694A1 (en) 2014-05-12
AU2012317325A1 (en) 2014-04-17

Similar Documents

Publication Publication Date Title
AU2012226981B2 (en) Method for producing glycopeptide having sialyl sugar chain, sialyl sugar chain-added amino acid derivative to be used in same, and glycopeptide
CN104936613B (zh) 糖链加成连接子、含有糖链加成连接子与生理活性物质的化合物或其盐、以及其制造方法
RU2636456C2 (ru) Гликозилированный полипептид и содержащая его фармацевтическая композиция
US20120114595A1 (en) Sugar chain-added ailim extracellular domain and method for producing same
EP2982686B1 (en) Polypeptide having sialylated sugar chains attached thereto